BRPI0519807A2 - uso de um canal trpc para o tratamento de uma doença cardiovascular - Google Patents

uso de um canal trpc para o tratamento de uma doença cardiovascular

Info

Publication number
BRPI0519807A2
BRPI0519807A2 BRPI0519807-0A BRPI0519807A BRPI0519807A2 BR PI0519807 A2 BRPI0519807 A2 BR PI0519807A2 BR PI0519807 A BRPI0519807 A BR PI0519807A BR PI0519807 A2 BRPI0519807 A2 BR PI0519807A2
Authority
BR
Brazil
Prior art keywords
cardiovascular disease
trpc channel
treat cardiovascular
trpc
channel
Prior art date
Application number
BRPI0519807-0A
Other languages
English (en)
Inventor
Carsten Struebing
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0519807A2 publication Critical patent/BRPI0519807A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM CANAL TRPC PARA O TRATAMENTO DE UMA DOENçA CARDIOVASCULAR. A presente invenção refere-se ao uso de um canal TRPC, um mutante inativo do mesmo, ou uma seqúência de nucleotídeo que codifica o canal TRPC ou o mutante inativo para a produção de um medicamento para o tratamento de uma doença cardiovascular e um método de triar um modulador do canal TRPC ou um mutante inativo do mesmo.
BRPI0519807-0A 2005-01-12 2005-12-23 uso de um canal trpc para o tratamento de uma doença cardiovascular BRPI0519807A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05000440 2005-01-12
PCT/EP2005/013977 WO2006074802A1 (en) 2005-01-12 2005-12-23 Use of a trpc channel for the treatment of a cardiovascular disease

Publications (1)

Publication Number Publication Date
BRPI0519807A2 true BRPI0519807A2 (pt) 2009-03-17

Family

ID=34933248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519807-0A BRPI0519807A2 (pt) 2005-01-12 2005-12-23 uso de um canal trpc para o tratamento de uma doença cardiovascular

Country Status (11)

Country Link
US (3) US20080221025A1 (pt)
EP (1) EP1838334A1 (pt)
JP (1) JP2008526905A (pt)
KR (1) KR20070094777A (pt)
CN (1) CN101098709B (pt)
AU (1) AU2005324908B2 (pt)
BR (1) BRPI0519807A2 (pt)
CA (1) CA2593603A1 (pt)
IL (1) IL184316A0 (pt)
MX (1) MX2007008428A (pt)
WO (1) WO2006074802A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
EP2368876A1 (en) 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
EP2556829B1 (en) 2011-08-10 2015-08-19 Universität Leipzig Bicyclic labdane diterpenes for use in the treatment of TRPC6 associated diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100110D0 (en) * 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
WO2002072824A2 (en) * 2001-02-20 2002-09-19 Bayer Aktiengesellschaft Human transient receptor potential channel protein.
AU2003251650A1 (en) * 2002-07-29 2004-02-23 Novartis Ag Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
JP2007511528A (ja) 2003-11-13 2007-05-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法

Also Published As

Publication number Publication date
JP2008526905A (ja) 2008-07-24
IL184316A0 (en) 2007-10-31
US20080221025A1 (en) 2008-09-11
AU2005324908B2 (en) 2011-03-24
US20110021377A1 (en) 2011-01-27
EP1838334A1 (en) 2007-10-03
CA2593603A1 (en) 2006-07-20
MX2007008428A (es) 2008-02-12
CN101098709B (zh) 2012-06-20
KR20070094777A (ko) 2007-09-21
US8030276B2 (en) 2011-10-04
WO2006074802A1 (en) 2006-07-20
US20110312874A1 (en) 2011-12-22
AU2005324908A1 (en) 2006-07-20
US8193150B2 (en) 2012-06-05
CN101098709A (zh) 2008-01-02

Similar Documents

Publication Publication Date Title
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
MY191407A (en) Certain chemical entities, compositions and methods
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
TW200738270A (en) Method of treating depression using a TNFα antibody
EP1651161A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR ACCELERATING WOUND HEALING
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2010006823A (es) Metodos para el tratamiento de la gota.
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
MX375132B (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2008036502A3 (en) Artificial spinal disc
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
TNSN08400A1 (en) Organic compounds and their uses
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
WO2008016666A3 (en) Certain chemical entities, compositions, and methods
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0508594A (pt) moduladores de canal de ìon
MX2009009693A (es) Metodos para activar irs-1 y akt.
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
UA88655C2 (ru) S-миртазапин для лечения прилива крови

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.